Table 3.
Antifibrotic treatment in individual countries.
|
Total N = 2492 |
Czech Republic N = 971 |
Turkey
N = 505 |
Poland N = 285 |
Hungary N = 216 |
Slovakia N = 149 |
Israel N = 120 |
Serbia N = 95 |
Croatia N = 87 |
Austria N = 55 |
Bulgaria N = 9 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pirfenidone | 750 (30.1%) | 364 (37.5%) T, P, HU, S, I, R, HR, A |
201 (39.8%) C, P, HU, S, I, A |
73 (25.6%) C, T, HU, S, I, A |
22 (10.2%) C, T, P, S, R, HR |
11 (7.4%) C, T, P, HU, I, R, HR |
20 (16.7%) C, T, P, S, R, HR |
27 (28.4%) C, HU, S, I, A |
25 (28.7%) C, HU, S, I, A |
6 (10.9%) C, T, P, R, HR |
1 (11.1%) |
| Nintedanib | 689 (27.6%) | 246 (25.3%) | 72 (14.3%) | 58 (20.4%) | 121 (56.0%) | 74 (49.7%) | 52 (43.3%) | 19 (20.0%) | 11 (12.6%) | 34 (61.8%) | 2 (22.2%) |
| Switch | 169 (6.8%) | 94 (9.7%) | 22 (4.4%) | 8 (2.8%) | 15 (6.9%) | 0 (0.0%) | 18 (15.0%) | 3 (3.2%) | 6 (6.9%) | 3 (5.5%) | 0 (0.0%) |
| None | 884 (35.5%) | 267 (27.5%) | 210 (41.6%) | 146 (51.2%) | 58 (26.9%) | 64 (43.0%) | 30 (25.0%) | 46 (48.4%) | 45 (51.7%) | 12 (21.8%) | 6 (66.7%) |
Data are N (%) or median (range). Data are only expressed as absolute number of patients and corresponding proportion percentage.